A medium-chain triglyceride containing ketogenic diet exacerbates cardiomyopathy in a CRISPR/Cas9 gene-edited rat model with Duchenne muscular dystrophy

被引:0
|
作者
Yuri Fujikura
Koichi Kimura
Keitaro Yamanouchi
Hidetoshi Sugihara
Masaki Hatakeyama
Haotong Zhuang
Tomoki Abe
Masao Daimon
Hiroyuki Morita
Issei Komuro
Katsutaka Oishi
机构
[1] National Institute of Advanced Industrial Science and Technology (AIST),Healthy Food Science Research Group, Cellular and Molecular Biotechnology Research Institute
[2] The University of Tokyo,Departments of Laboratory Medicine / Cardiology, The Institute of Medical Science
[3] The University of Tokyo,Department of Veterinary Physiology, Graduate School of Agricultural and Life Sciences
[4] Miyagi Health Innovation,Department of Cardiovascular Medicine, Graduate School of Medicine
[5] The University of Tokyo,Department of Applied Biological Science, Graduate School of Science and Technology
[6] Tokyo University of Science,Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences
[7] The University of Tokyo,School of Integrative and Global Majors (SIGMA)
[8] University of Tsukuba,undefined
来源
Scientific Reports | / 12卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Duchenne muscular dystrophy (DMD) is an X-linked recessive myopathy caused by dystrophin mutations. Although respiratory management has improved the prognosis of patients with DMD, inevitable progressive cardiomyopathy is a current leading cause of premature death. Recently, we showed that a medium-chain triglyceride containing ketogenic diet (MCTKD) improves skeletal muscle function and pathology in a CRISPR/Cas9 gene-edited rat model with DMD. In this study, we sought to clarify whether MCTKD also improves the cardiomyopathy in these rats. DMD rats were fed either the MCTKD or normal diet (ND) from ages of 3 weeks to 9 months old. Compared with the ND-fed rats, MCTKD-fed rats showed significantly prolonged QRS duration, decreased left ventricular fractional shortening, an increased heart weight/body weight ratio, and progression of cardiac fibrosis. In contrast to our previous study which found that MCTKD improved skeletal myopathy, the current study showed unexpected exacerbation of the cardiomyopathy. Further studies are needed to explore the underlying mechanisms for these differences and to explore modified dietary options that improve skeletal and cardiac muscles simultaneously.
引用
收藏
相关论文
共 38 条
  • [21] Delivery of a Multiplex CRISPR/Cas9 Machinery for the Treatment of Duchenne Muscular Dystrophy with One Single Gene Deleted Adenoviral Vector
    Ehrke-Schulz, Eric
    Mouly, Vincent
    Kley, Rudolph A.
    Ehrhardt, Anja
    MOLECULAR THERAPY, 2018, 26 (05) : 329 - 330
  • [22] Delivery of a multiplex CRISPR/Cas9 machinery for the treatment of Duchenne muscular dystrophy with one single gene deleted adenoviral vector
    Ehrke-Schulz, E.
    Mouly, V.
    Kley, R. A.
    Ehrhardt, A.
    HUMAN GENE THERAPY, 2017, 28 (12) : A40 - A40
  • [23] Delivery of CRISPR/Cas9 via Viral and Non-Viral Methods to Reframe the DMD Gene in a Humanized Mouse Model of Duchenne Muscular Dystrophy
    Young, Courtney S.
    Ji, Ying
    Liu, Xiangsheng
    Mokhonova, Ekaterina
    Emami, Michael
    Bengtsson, Niclas
    Chamberlain, Jeffrey S.
    Pyle, April D.
    Meng, Huan
    Spencer, Melissa J.
    MOLECULAR THERAPY, 2018, 26 (05) : 396 - 396
  • [24] Correction of a common Duchenne muscular dystrophy mutation by CRISPR/Cas9 gene editing using homology-independent targeted integration
    Nicolau, S.
    Sarff, J.
    Vetter, T.
    Stephenson, A.
    Flanigan, K.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [25] Dystrophin Restoration in a Humanized Mouse Model of Duchenne Muscular Dystrophy by Gene Editing with S. Aureus Cas9
    Robinson-Hamm, Jacqueline N.
    Nelson, Christopher E.
    Gemberling, Matthew
    Gough, Veronica
    Rivera, Ruth M. Castellanos
    Aartsma-Rus, Annemieke
    Asokan, Aravind
    Gersbach, Charles A.
    MOLECULAR THERAPY, 2018, 26 (05) : 118 - 119
  • [26] Dystrophin Restoration in a Humanized Mouse Model of Duchenne Muscular Dystrophy by Gene Editing with S. aureus Cas9
    Robinson-Hamm, Jacqueline N.
    Nelson, Christopher E.
    Gemberling, Matthew
    Rivera, Ruth M. Castellanos
    Aartsma-Rus, Annemieke
    Asokan, Aravind
    Gersbach, Charles A.
    MOLECULAR THERAPY, 2017, 25 (05) : 17 - 17
  • [27] Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy (vol 8, 14454, 2017)
    Bengtsson, Niclas E.
    Hall, John K.
    Odom, Guy L.
    Phelps, Michael P.
    Andrus, Colin R.
    Hawkins, R. David
    Hauschka, Stephen D.
    Chamberlain, Joel R.
    Chamberlain, Jeffrey S.
    NATURE COMMUNICATIONS, 2017, 8
  • [28] A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing
    Zhang, Yu
    Li, Hui
    Nishiyama, Takahiko
    McAnally, John R.
    Sanchez-Ortiz, Efrain
    Huang, Jian
    Mammen, Pradeep P. A.
    Bassel-Duby, Rhonda
    Olson, Eric N.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2022, 29 : 525 - 537
  • [29] A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing
    Zhang, Yu
    Li, Hui
    Nishiyama, Takahiko
    McAnally, John R.
    Sanchez-Ortiz, Efrain
    Huang, Jian
    Mammen, Pradeep P. A.
    Bassel-Duby, Rhonda
    Olson, Eric N.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2022, 29 : 525 - 537
  • [30] CRISPR/Cas9-Mediated Gene-Editing Rescues Dystrophin Expression in a Dog Model of Duchenne Muscular Dystrophy
    Maruyama, Rika
    Quynh Nguyen
    Aoki, Yoshitsugu
    Takeda, Shin'ichi
    Yokota, Toshifumi
    MOLECULAR THERAPY, 2018, 26 (05) : 121 - 121